Labcorp Holdings Inc.

Equities

LH

US5049221055

Healthcare Facilities & Services

Market Closed - Nyse Other stock markets 01:30:02 29/06/2024 am IST			5-day change	1st Jan Change
203.5 ^USD	-0.68%		-0.85%	-10.46%

17/06	Labcorp Launches Labcorp Global Trial Connect to Accelerate Clinical Trials	CI
13/06	Baird Adjusts Price Target on Laboratory Corp of America Holdings to $258 From $256	MT

LABORATORY CORP OF AMERICA HOLDINGS : Regulation FD Disclosure (form 8-K)

January 04, 2023 at 03:06 am IST

Item 7.01 Regulation FD Disclosure

Labcorp (NYSE: LH), a leading global life sciences company, today announced that members of the executive management team will participate in a fireside chat at the 41st Annual J.P. Morgan Healthcare Conference on Tuesday, Jan. 10 at 4:30 p.m. (PT).



A live audio webcast of the fireside chat will be available via the Company
Investor Relations website at ir.Labcorp.com and archived for replay.
Item 9.01            Financial Statements and Exhibits.

Exhibit              Exhibit Name
Exhibit 99.1           Press Release dated     January 3,     2023     issued by Labcorp

--------------------------------------------------------------------------------

Latest news about Labcorp Holdings Inc.

Labcorp Launches Labcorp Global Trial Connect to Accelerate Clinical Trials	17/06	CI
Baird Adjusts Price Target on Laboratory Corp of America Holdings to $258 From $256	13/06	MT
HSBC Adjusts Price Target on Laboratory Corp of America Holdings to $210 From $225, Keeps Hold Rating	05/06	MT
Transcript : Labcorp Holdings Inc. Presents at The 44th Annual William Blair Growth Stock Conference, Jun-04-2024 02:00 PM	05/06
Labcorp Holdings Inc. Announces New Strategic Service Offerings Within Precision Oncology Portfolio	03/06	CI
JPMorgan Adjusts Price Target on Laboratory Corp of America Holdings to $243 From $261	30/05	MT
Some of the biggest splits in Corporate America	23/05	RE
Declaration of Voting Results by Laboratory Corporation of America Holdings	17/05	CI
Declaration of Voting Results by Laboratory Corporation of America Holdings	17/05	CI
Declaration of Voting Results by Laboratory Corporation of America Holding	17/05	CI
Laboratory Corp Of America Holdings Insider Sold Shares Worth $421,655, According to a Recent SEC Filing	16/05	MT
Baird Adjusts Price Target on Laboratory Corp of America Holdings to $256 From $255, Keeps Outperform Rating	16/05	MT
Labcorp Introduces First Trimester Screening Test to Assess Preeclampsia Risk During Pregnancy	15/05	CI
Tara Health Files an Exempt Solicitation Statement and Recommend Vote for its Proposal	07/05	CI
Tranche Update on Laboratory Corporation of America Holdings (NYSE:LH)'s Equity Buyback Plan announced on December 9, 2021.	30/04	CI
Baird Adjusts Laboratory Corp of America Holdings' Price Target to $255 From $244	30/04	MT
Labcorp Receives US FDA's Approval for Companion Diagnostic Device for Use With Pfizer's Hemophilia B Gene Therapy	29/04	MT
US FDA publishes final rule for laboratory developed tests	29/04	RE
Labcorp Receives FDA Approval for First Companion Diagnostic for Use with Pfizer's Newly Approved Gene Therapy to Treat Patients with Hemophilia B	29/04	CI
Baird Adjusts Laboratory Corp of America Holdings' Price Target to $244 From $255	26/04	MT
Barclays Adjusts Price Target on Laboratory Corp of America Holdings to $213 From $234	26/04	MT
Truist Cuts Price Target on Laboratory Corp of America Holdings to $255 From $270, Keeps Buy Rating	26/04	MT
Evercore ISI Cuts Laboratory Corp of America Holdings' Price Target to $210 From $225	26/04	MT
Leerink Partners Adjusts Laboratory Corp of America Price Target to $242 From $260, Keeps Outperform Rating	25/04	MT
Laboratory Corp of America Q1 Adjusted Earnings, Revenue Increase; 2024 Adjusted EPS Outlook Updated	25/04	MT

Chart Labcorp Holdings Inc.

Duration

Period

More charts

Company Profile

Labcorp Holdings Inc. provides comprehensive laboratory services that provides vital information to help doctors, hospitals, pharmaceutical companies, researchers, and patients make clear and confident decisions. By leveraging its unparalleled diagnostics and drug development capabilities, the Company provides insights and accelerates innovations to improve health and improve lives. The Company operates through two segments: Diagnostics Laboratories (Dx) and Biopharma Laboratory Services (BLS). The Diagnostics Laboratories segment includes routine testing and specialty/esoteric testing. Dx operates through a network of patient service centers, branches, rapid response laboratories, primary laboratories, and specialty laboratories. The Biopharma Laboratory Services segment consists of early development research laboratories and central laboratory services. The Company serves clients in more than 100 countries.

Sector

Healthcare Facilities & Services

More about the company

Income Statement Evolution

More financial data

Ratings for Labcorp Holdings Inc.

Trading Rating

Investor Rating

ESG Refinitiv

More Ratings

Analysts' Consensus

Sell

Buy

Mean consensus

BUY

Number of Analysts

Last Close Price

203.5 USD

Average target price

237.6 USD

Spread / Average Target

+16.75%

Consensus

EPS Revisions

Estimates Revisions

Quarterly earnings - Rate of surprise

Company calendar

Sector Other Healthcare Facilities & Services

	1st Jan change	Capi.
LABCORP HOLDINGS INC.	-10.46%	1.72TCr
HCA HEALTHCARE, INC.	+18.69%	8.41TCr
CVS HEALTH CORPORATION	-25.20%	7.41TCr
DR. SULAIMAN AL HABIB MEDICAL SERVICES GROUP COMPANY	+1.06%	2.68TCr
FRESENIUS SE & CO. KGAA	-0.68%	1.68TCr
QUEST DIAGNOSTICS INCORPORATED	-0.73%	1.52TCr
NATERA, INC.	+72.88%	1.33TCr
TENET HEALTHCARE CORPORATION	+76.04%	1.3TCr
PURE HEALTH HOLDING	-25.96%	1.28TCr
UNIVERSAL HEALTH SERVICES, INC.	+21.31%	1.24TCr

Other Healthcare Facilities & Services